Basic, Translational research Imaging Methodology Development (BRIDGE) Programme
At the dawn of personalized medicine, medical imaging is becoming a key tool to diagnose and select the best treatment for the individual patient. This is especially of interest for the vulnerable population, including the elderly patients. Not only fast and accurate diagnosis, but also the decision of viable treatment is crucial.

See. Understand. Treat.

We develop medical imaging solutions to improve treatment effectiveness using state-of-the-art technology, software analysis tools and big data. Our research activities bridge the stage of early development all the way into clinical practice.

In our BRIDGE research programme, we bring together clinical imaging experts, IT experts, imaging methodology experts, basic scientists and clinicians. Together we see, understand and treat.

  • See by using new imaging biomarker development and validation
  • Understand through quantification, standardisation and informatics
  • Treat using image-guided therapy and connecting diagnostics and therapy (theranostics)



Medical imaging enables personalized treatment for our patients

Personalized medicine has become the cornerstone in the medical community by optimizing treatment for each patient. Our advanced medical imaging solutions not only contribute to the improved treatment of oncological diseases, but are also increasingly important in the fields of infection and inflammation, cardiology and neurology.

We use medical imaging in prevention, early detection, staging, and therapy, thus helping clinicians select the best treatment for the individual patient. Within BRIDGE we bring together all the people in this field, from basic scientists to methodological experts, translational experts,  imaging specialists and clinicians. Jointly we develop innovative biomarkers and techniques, all with just one aim: helping our patients.

  • To translate and implement new imaging biomarkers, we need to demonstrate their mechanism, assess their performance and robustness, determine the optimal way of data collection and assess its clinical value.

    • We develop new optical imaging agents, radiotracers, MRI contrast agents and new MRI sequences and CT techniques.
    • We develop new imaging and spectroscopy modalities including nanoscale MRI.
    • We facilitate and support those research activities that will translate new imaging biomarkers from bench to bed-side.
  • With our research, we standardize, validate, calibrate and test measurement methods to guarantee reproducibility and result robustness.

    • We develop quantitative imaging methodology, analysis methods and imaging procedures that can extract data from images.
    • We train machine and deep learning algorithms to recognize specific patterns or diagnostic information from a large set of data.
    • We apply medical informatics to link images with non-imaging data, covering deep learning as well as other medical informatics activities such as 3D printing, advanced 3D visualisations, image storage and analysis infrastructures.
    • We use advanced medical informatics systems to guide therapies.
  • Imaging has become an integral part of the work-up in patient care and therapy. This ranges from diagnosis, treatment prediction, selection and planning, response monitoring and the assessment of tissue damage. We use imaging to help identify patients that may more likely benefit from complex treatments, thereby avoiding unnecessary or inappropriate treatments.

    • We study the use of imaging in diagnosis (drug, radio- and proton), therapy decision making, surgery and image guided surgery.
    • We connect diagnostics and therapy (theranostics), for example through the development of photopharmacology.